Genzyme Closes Ilex Deal After FTC Orders “Creative” Campath Divestiture
Executive Summary
Genzyme will be precluded from any involvement with Campath (alemtuzumab) in the organ transplant rejection therapy market under a consent order with the Federal Trade Commission allowing the company to complete the acquisition of Ilex